Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer.
Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer.
Allison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.
In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.
During AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.
In this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS’s role in developing an ASCO/NCCN guideline for their management.
Cancer patients get inundated with advice, but how much of it can be trusted? Patient advocate Suzie Siegel weighs in.
MSKCC’s Dr. Nancy Kemeny discusses the impact of a company's decision to halt manufacture of a pump used to treat liver mets from colon and rectal cancers.
Updates to the 8th edition of AJCC's staging manual include incorporation of more nonanatomic features. Oncology Clinical Specialist Chelsea Backler discussed key changes during the 2018 ONS Congress.
Alisa Domb highlighted training and workflow optimization for an ambulatory-setting navigation program covering 10 hem/onc clinics and 2 cancer centers, during the 2018 ONS Congress.
Joshua Brody discusses ECHELON-1 and its subanalyses, the results of which are anticipated to change the management of Hodgkin lymphoma.
In this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.
Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.
An oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.
Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
An oncology pharmacist talks secondary malignancies noted with tazemetostat in the treatment of follicular lymphoma.
This article reviews how acupuncture is thought to work, data on acupuncture for managing pain caused by cancer or by cancer treatment, how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
USPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
Late last year, ONCOLOGY hosted a writing contest on Cancer Network, in which we asked our readers to share their personal experiences with delivering bad news. Dr. Trevor Bayliss submitted a piece about his experience as a young patient, and how that influenced his decision to become an oncologist.
In this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.
In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
This lesion started as a rash 3 months prior to presentation and became an ulcerated open wound with some nodularity in and around it. What is your diagnosis?
Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.